Overexpression of ANGPTL4 and injection of recombinant ANGPTL4 lead to hypertriglyceridemia in mice (25, 26, 27, 28), whereas antibody-mediated inactivation, genetic silencing, and complete genetic ablation of ANGPTL4 significantly decrease plasma TG levels (25, 29, 30, 31). Here, ANGPTL4 is linked to hypertriglyceridemia.